Dr Rachael Shepherd

Cell Biologist
Phone - +61 2 9717 3023
   
Dr Rachael Shepherd

Profile

Role at ANSTO

 
Rachael’s current role is in applying in vitro and in vivo techniques to investigate the impact of radiation on living matter. Rachael also supports the evaluation of novel radiotracers in living systems.
 

Background

 
Before joining ANSTO, Rachael completed her PhD at the University of Sydney in which she investigated the role of apoptosis in the pathophysiology of mitochondrial disorders. In 2005, Rachael joined ANSTO LifeSciences (formerly known as the Radiopharmaceutical Research Institute) as a Research Scientist to characterise novel radiotracers and potential drug targets using in vitro and in vivo techniques. 
 

Research interests and areas of expertise

 
Rachael’s areas of expertise include cell culture, immunofluorescence assays, histology, radioligand binding assays, radiotracer cell uptake assays, and in vivo radiotracer analysis.  
 

Qualifications & Achievements

 

PhD (2007) University of Sydney
BBiotech (Hons) (1999) University of Wollongong

 

Selected publications

 

Pellegrini, P. A., Howell, N. R., Shepherd, R. K., Lengkeek, N. A., Oehlke, E., Katsifis, A. G., Greguric, I. Synthesis and radiolabelling of DOTA-linked glutamine analogues with 67,68Ga as markers for increased glutamine metabolism in tumour cells. Molecules, 18(6), 7160-7178 (2013). doi: 10.3390/molecules18067160


Nguyen, V. H., Pham, T., Fookes, C., Berghofer, P., Greguric, I., Arthur, A., Mattner, F., Rahardjo, G., Davis, E., Howell, N., Gregoire, M-C., Katsifis, A., Shepherd, R. Synthesis and biological characterisation of 18F-SIG343 18F-SIG353, novel and high selectivity sigma2 radiotracers, for tumour imaging properties. EJNMMI Research, 3(1), 80 (2013). doi: 10.1186/2191-219X-3-80


Denoyer, D., Kirby, L., Waldeck, K., Roselt, P., Neels, O. C., Bourdier, T., Shepherd, R., Katsifis, A., Hicks, R. J. Preclinical characterization of 18F-D-FPHCys, a new amino acid-based PET tracer. Eur J Nucl Med Mol Imaging, 39(4): 703-712. (2012)


Ranson, M., Berghofer, P., Vine, K. L., Greguric, I., Shepherd, R., Katsifis, A. Different radiolabelling methods alter the pharmacokinetic and biodistribution properties of Plasminogen Activator Inhibitor Type 2 (PAI-2) forms. Nuclear Medicine and Biology, 39: 833-839. (2012)


Bourdier, T., Shepherd, R., Berghofer, P., Jackson, T., Fookes, C. J., Denoyer, D., Dorow, D., Greguric, I., Gregoire, M-C., Hicks, R. J., Katsifis, A. Radiosynthesis and biological evaluation of L and D S-(3-[18F]Fluoropropyl)-homocysteine for tumor imaging using positron emission tomography. Journal of Medicinal Chemistry, 54(6), 1860-1870. (2011)


Fookes, C. J. R., Pham, T. Q., Mattner, F., Greguric, I., Loc’h, C., Liu, X., Berghofer, P., Shepherd, R., Gregoire, M-C., Katsifis, A. Synthesis and biological evaluation of substituted [18F]Imidazo[1,2-a]pyridines and [18F]Pyrazolo[1,5-a]pyrimidines for the study of the Peripheral Benzodiazepine Receptor using Positron Emission Tomography. Journal of Medicinal Chemistry, 51(13): 3700-3712. (2008)